Provided by Tiger Trade Technology Pte. Ltd.

Centessa Pharmaceuticals plc

28.70
-0.7000-2.38%
Post-market: 28.00-0.7000-2.44%19:39 EDT
Volume:1.39M
Turnover:40.43M
Market Cap:4.19B
PE:-15.76
High:29.93
Open:29.35
Low:28.68
Close:29.40
52wk High:30.58
52wk Low:9.60
Shares:146.00M
Float Shares:97.13M
Volume Ratio:0.82
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8212
EPS(LYR):-2.0595
ROE:-60.62%
ROA:-25.26%
PB:13.89
PE(LYR):-13.94

Loading ...

Centessa Pharmaceuticals (CNTA): Assessing Valuation After a 44% Three-Month Share Price Surge

Simply Wall St.
·
Nov 14, 2025

Centessa Pharmaceuticals Chief Technology & Quality Officer Tia L. Bush Reports Common Share Disposal

Reuters
·
Nov 14, 2025

Sector Update: Health Care Stocks Higher in Afternoon Trading

MT Newswires Live
·
Nov 13, 2025

Centessa rises 14.0%

TIPRANKS
·
Nov 13, 2025

European Equities Traded in the US as American Depositary Receipts Rise Wednesday

MT Newswires Live
·
Nov 13, 2025

Stock Track | Centessa Pharmaceuticals Soars 5.26% Pre-Market Despite $250 Million Share Offering

Stock Track
·
Nov 12, 2025

Stock Track | Centessa Pharmaceuticals Plunges 5.06% Pre-market Following $250 Million Share Offering

Stock Track
·
Nov 12, 2025

Press Release: Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Dow Jones
·
Nov 12, 2025

Stock Track | Centessa Pharmaceuticals Plunges 5.32% as Analysts Predict Continued Losses

Stock Track
·
Nov 08, 2025

Centessa Pharmaceuticals PLC expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Centessa Pharmaceuticals to Participate in Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 07, 2025

Centessa Pharmaceuticals Slips on Disappointing 3Q Results

Dow Jones
·
Nov 06, 2025

RBC says Centessa data highlights ‘impressive profile’ of Alkermes’ alixorexton

TIPRANKS
·
Nov 06, 2025

Centessa Pharmaceuticals Down Over 16%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk

Dow Jones
·
Nov 06, 2025

Centessa Pharmaceuticals reports Q3 results and updates OX2R agonist program

Reuters
·
Nov 05, 2025

Stephens Initiates Centessa Pharmaceuticals at Overweight

MT Newswires Live
·
Oct 28, 2025

Centessa Pharmaceuticals Plc : Stephens Initiates Coverage With Overweight Rating; Price Target $35

THOMSON REUTERS
·
Oct 28, 2025

Centessa Pharmaceuticals Initiated at Overweight by Stephens & Co.

Dow Jones
·
Oct 28, 2025

Centessa initiated with an Overweight at Stephens

TIPRANKS
·
Oct 28, 2025

Mario Alberto Accardi, President of Orexin Program, Sells Centessa Pharmaceuticals plc Common Shares

Reuters
·
Oct 28, 2025